A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRASG12D Inhibitor MRTX1133 | Citedby Results | Cancer Research | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

A Nonconserved Histidine Residue on KRAS Drives Paralog Selectivity of the KRAS^G12D Inhibitor MRTX1133

Cancer Res (2023) 83 (17): 2816–2823.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D

Qinheng Zheng
Ziyang Zhang
Keelan Z. Guiley
Kevan M. Shokat

Nature Chemical Biology (2024) 20 (9): 1114.

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer

Daoyan Wei
Liang Wang
Xiangsheng Zuo
Anirban Maitra
Robert S. Bresalier

Clinical Cancer Research (2024) 30 (4): 655.

KRAS inhibitors in drug resistance and potential for combination therapy

Lala S. Rathod
Nikhil S. Sakle
Santosh N. Mokale

Tumori Journal (2024)

Ability of 18F-FDG Positron Emission Tomography Radiomics and Machine Learning in Predicting KRAS Mutation Status in Therapy-Naive Lung Adenocarcinoma

Ruiyun Zhang
Kuangyu Shi
Wolfgang Hohenforst-Schmidt
Claus Steppert
Zsolt Sziklavari
Christian Schmidkonz
Armin Atzinger
Arndt Hartmann
Michael Vieth
Stefan Förster

Cancers (2023) 15 (14): 3684.